Innate Pharma SA (IPHA) Actualités

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Innate Pharma présente ses résultats financiers au troisième trimestre 2024

Jonathan Dickinson est nommé Président du Directoire d’Innate Pharma Innate a reçu une réponse préliminaire encourageante de la FDA1 concernant...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Innate Pharma Highlights Data From Its Innovative Oncology Portfolio Selected for the SITC Annual Meeting 2024

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that new preclinical data...

Innate Pharma Announces Conference Call and Webcast for Third Quarter 2024 Results and Business Updates

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that the Company will hold a...

Innate Pharma Announces Its Participation in Upcoming Investor Conferences

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that members of its executive...

Innate Pharma Appoints Jonathan Dickinson as New Chief Executive Officer and Chairman of the Executive Board

Jonathan Dickinson joins Innate on November 1 and brings broad experience from leadership roles in biotech and big pharma Current interim CEO...

Innate Pharma co-organise un symposium scientifique en présence d’experts de l’Immunotherapie à New York le 3 octobre 2024

Regulatory News: Innate Pharma SA (Euronext Paris : IPH; Nasdaq : IPHA) (« Innate » ou la « Société ») partage des détails concernant...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]